Search bioRxiv⌕ Search

Biology subjects

Michael, G.

Publications and source records attributed to Michael, G..

2 recordsLinked to original sources

A tissue time machine to forward-predict single-timepoint data applied to tuberculosis granulomas

Recent advances have improved understanding of infection; however many detailed datasets are based on single timepoints post-infection and cannot generate longitudinal insights needed to predict infection outcomes. For example, pulmonary infection with Mycobacterium tuberculosis (Mtb) initiates a complex system of immune and bacterial interactions that leads to granuloma formation, yet single snapshots in time need elaboration long-term. We develop a new approach, the tissue time machine, applied to predict outcomes of non-human primate granulomas from initiation to endpoint using single timepoint tissue datasets including high-dimensional spatial features. This involves identifying granuloma digital partners, simulations most closely resembling real granulomas from a virtual library of over 50,000. By analyzing digital partners, we predict infection outcomes of 22/28 granulomas, and that Mtb-specific, IFN-{gamma}-producing T cell recruitment rates influence uncertainty for the 6/28. This method is applicable to any system that allows for mechanistic predictions over time using heterogeneous, incomplete, and high-dimensional datasets.

systems biology↗

Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant

The emergence of SARS-CoV-2 variants with mutations in the spike protein is raising concerns about the efficacy of infection- or vaccine-induced antibodies to neutralize these variants. We compared antibody binding and live virus neutralization of sera from naturally infected and spike mRNA vaccinated individuals against a circulating SARS-CoV-2 B.1 variant and the emerging B.1.351 variant. In acutely-infected (5-19 days post-symptom onset), convalescent COVID-19 individuals (through 8 months post-symptom onset) and mRNA-1273 vaccinated individuals (day 14 post-second dose), we observed an average 4.3-fold reduction in antibody titers to the B.1.351-derived receptor binding domain of the spike protein and an average 3.5-fold reduction in neutralizing antibody titers to the SARS-CoV-2 B.1.351 variant as compared to the B.1 variant (spike D614G). However, most acute and convalescent sera from infected and all vaccinated individuals neutralize the SARS-CoV-2 B.1.351 variant, suggesting that protective immunity is retained against COVID-19.

immunology↗